15:37 , May 4, 2018 |  BC Week In Review  |  Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
19:46 , Apr 30, 2018 |  BC Extra  |  Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II trials...
19:21 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
00:25 , Jun 21, 2017 |  BC Extra  |  Company News

Management tracks

Biogen Inc. (NASDAQ:BIIB) named Ginger Gregory EVP and chief human resources officer, effective July 17. She was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB (SSE:ACTI) promoted...
02:10 , Feb 11, 2017 |  BioCentury  |  Product Development

Form(ulation) follows function

A clinical study of two formulations of marketed drug Linzess linaclotide supports Ironwood Pharmaceuticals Inc.’s hypothesis that pain in irritable bowel syndrome with constipation is not due to constipation alone, but also to hypersensitive nerves...
18:54 , Nov 4, 2016 |  BioCentury  |  Finance

Third Rock’s wellspring

By sticking to its script of forming early stage big idea companies, Third Rock Ventures raised a $616 million fund in a matter of months and believes its company-building efforts will be rewarded regardless of...
07:00 , Sep 19, 2016 |  BioCentury  |  Product Development

Getting ahead of headache

After several false starts, investments in CGRP inhibitors are bearing fruit in the clinic - if not exactly the prize pumpkins once hoped for from the class. Still, if the sponsors developing these products can...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Company News

Afferent, Merck deal

Merck will acquire Afferent for $500 million in cash and up to $750 million in clinical and commercialization milestones for candidates in Afferent’s pipeline, including AF-219. AF-219, a purinergic receptor P2X ligand-gated ion...
01:26 , Jun 10, 2016 |  BC Extra  |  Top Story

Merck acquiring Afferent

Merck & Co. Inc. (NYSE:MRK) is acquiring Afferent Pharmaceuticals Inc. (San Mateo, Calif.) for $500 million in cash. The deal gives the pharma Afferent's chronic cough candidate AF-219, a purinergic receptor P2X ligand-gated ion channel...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

AF-130: Phase I started

Afferent began a 2-part, double-blind, placebo-controlled, U.K. Phase I trial to evaluate oral AF-130 in about 109 healthy volunteers. The first part will evaluate single ascending doses of AF-130 in about 64 healthy volunteers. The...